Ask AI

Recent Advances in BCMA-Targeted Agents for R/R MM

Text Module
Text Module Start Activity
This activity is available for 0.50 CME/CE credit(s).

Released: August 14, 2026

Expiration: February 13, 2027

See Activity Collection

Experts review what oncology pharmacists need to know about the rationale for targeting BCMA in R/R MM and the latest evidence supporting the utility of BCMA-targeted agents in the management of patients with R/R MM, including efficacy results from the DREAMM-7, DREAMM-8, CARTITUDE-1, CARTITUDE-4, iMMagine-1, MajesTEC-1, MajesTEC-3, MagnetisMM-3 and LINKER-MM1 trials and highlight key ongoing trials of approved and investigational BCMA-directed agents in MM.

Targeting BCMA in RR MM

Pre Assessment

Assess your current knowledge and clinical approach before beginning your text module.
1.

Which of the following best explains the rationale for targeting BCMA to improve outcomes in patients with early R/R MM?

2.

A 66-year-old woman was diagnosed with IgG kappa MM with t(14;16). She was initially treated with lenalidomide, bortezomib, dexamethasone followed by autologous stem cell transplant (ASCT) and lenalidomide maintenance. She experienced biochemical relapse after 5 years of maintenance therapy and received daratumumab, pomalidomide, dexamethasone (DPd) for 1 year. Over the past several months, her M-spike has been slowly increasing and has now risen to >0.5 g/dL, indicating disease relapse. She is not interested in undergoing intensive treatment, including a second ASCT or CAR T-cell therapy.

In your discussion with this patient, which of the following would you tell her is the most appropriate third-line treatment option for her disease?